September 26, 2016
Whitehead Institute scientists have devised a protocol for pushing human pluripotent stem cells to become microglia—the specialized immune cells that maintain the brain and care for it after injury. Microglia play an important role in neurodegenerative diseases, including Parkinson’s and Alzheimer’s, and studying these cells has been very difficult until now.
September 22, 2016
Whitehead Institute scientists have deciphered how to use a modified CRISPR/Cas9 gene editing system to change genes’ methylation state, thereby activating or silencing those genes. Proper methylation is critical for normal cellular operations and altered methylation has been linked to many diseases, including neurological disorders and cancer.
Inherited parental methylation shifts over time, may have functional effects in the brain and other tissues
September 20, 2016
Inherited methylation—a form of epigenetic regulation passed down from parents to offspring—is far more dynamic than previously thought and may contribute to changes in the brain and other tissues over time. This finding by Whitehead Institute scientists challenges current understandings of gene regulation via methylation, from development through adulthood.
Former Mass. Governor Deval Patrick, life sciences executive Amy Schulman join Whitehead Institute Board of Directors
September 15, 2016
Whitehead Institute announced today that Deval Patrick, a Bain Capital managing director and former Massachusetts governor, and Amy Schulman, a distinguished life sciences executive, have been elected to its Board of Directors.
September 1, 2016
Whitehead Institute researchers have conducted the first genome-wide screen in Apicomplexa, a phylum of single-celled parasites that cause diseases such as malaria and toxoplasmosis. The screen sheds light into the vast, unstudied reaches of parasite genomes, uncovering for instance a protein common to all apicomplexans.
August 31, 2016
Whitehead Institute scientists have developed a method to quickly isolate mitochondria from mammalian cells and systematically measure the concentrations of mitochondrial metabolites. Mitochondrial dysfunction is found in several disorders, including Parkinson’s disease, cardiovascular disease, and mitochondrial diseases. Until now, peering into the inner metabolic workings of these vital organelles has been very challenging.
August 11, 2016
By identifying new compounds that selectively block mitochondrial respiration in pathogenic fungi, Whitehead Institute scientists have identified a potential antifungal mechanism that could enable combination therapy with fluconazole, one of today’s most commonly prescribed fungal infection treatments. Severe, invasive fungal infections have a mortality rate of 30-50% and cause an estimated 1.5 million deaths worldwide annually. Current antifungal therapies are hampered by the increasingly frequent emergence of drug resistance and negative interactions that often preclude combination use.
August 3, 2016
Whitehead Institute Member Susan Lindquist has been named one of three recipients of the Albany Medical Center Prize in Medicine and Biomedical Research for 2016.
August 2, 2016
Whitehead Institute researchers have identified an area in the developing face of embryonic frogs that unzips to form the mouth. The scientists, who named this region the “pre-mouth array”, have also discovered the cellular signaling that triggers its formation. Elucidating this critical aspect of craniofacial development in a model organism enhances understanding of and potential treatment for human facial birth defects.
July 18, 2016
Whitehead Member Jing-Ke Weng is one of eight early-career scientists nationwide to be named a 2016 Beckman Young Investigator.
July 14, 2016
Whitehead Institute scientists have created a checklist that defines the “naive” state of cultured human embryonic stem cells (ESCs). Such cells provide a better model of early human embryogenesis than conventional ESCs in later stages of development.
July 4, 2016
MIT and Whitehead Institute scientists have developed a new type of easily customizable vaccine that can be manufactured in one week, allowing it to be rapidly deployed in response to disease outbreaks. So far, they have designed vaccines against Ebola, H1N1 influenza, and Toxoplasma gondii (a relative of the parasite that causes malaria), which were 100 percent effective in tests in mice.